Rocket Pharma counsel sells 12,253 company shares

ROCKET PHARMACEUTICALS, INC.

Accepted by SEC EDGAR 02/18/2026 - 05:42 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

ROCKET PHARMACEUTICALS, INC. General Counsel Wilson Martin sold 12,253 shares of common stock on February 13, 2026 in an open-market transaction at an average price of $3.312 per share. According to the disclosure, the sale was made to pay tax withholding obligations tied to the vesting of restricted stock units (RSUs). After this transaction, Martin directly owned 683,376 shares, and his holdings include RSUs that convert into common stock on a one-for-one basis.

Insider Trade Summary

Net Seller: 12,253 shares

Net Sell 1 txn

Insider Wilson Martin

Role General Counsel

Sold 12,253 shs ($41K)

Share of Position Sold 1.8%

Type	Security	Shares	Price	Value
Sale	Common Stock	12,253	$3.312	$41K

Holdings After Transaction: Common Stock — 683,376 shares (Direct)

Holdings Before and After: Common Stock, 695,629 to 683,376 shares (Direct)

Other Insiders: 2 other insiders reported open-market sales of this stock in the 30 days up to this filing.

Footnotes (2)

1. F1. Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis.
2. F2. The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Rocket Pharmaceuticals (RCKT) insider Wilson Martin report on this Form 4?

Wilson Martin, General Counsel of Rocket Pharmaceuticals, reported selling 12,253 shares of common stock. The shares were sold on February 13, 2026, and the filing notes the sale was made to satisfy tax withholding obligations from vesting restricted stock units.

How many Rocket Pharmaceuticals (RCKT) shares did Wilson Martin sell and at what price?

Wilson Martin sold 12,253 shares of Rocket Pharmaceuticals common stock. The reported average sale price was approximately $3.312 per share, reflecting an open-market or private transaction as classified under transaction code “S” in the filing.

Why did Wilson Martin sell Rocket Pharmaceuticals (RCKT) shares according to the Form 4?

The filing states that the shares were sold to pay tax withholding obligations. These obligations arose in connection with the vesting of restricted stock units (RSUs), which convert into Rocket Pharmaceuticals common stock on a one-for-one basis when they vest.

How many Rocket Pharmaceuticals (RCKT) shares does Wilson Martin hold after this transaction?

After the reported sale, Wilson Martin beneficially owned 683,376 shares of Rocket Pharmaceuticals common stock. The disclosure explains that his holdings include restricted stock units that convert into common stock at a one-for-one ratio upon vesting.

What type of transaction is reported in Wilson Martin’s Rocket Pharmaceuticals (RCKT) Form 4?

The Form 4 reports a non-derivative transaction in Rocket Pharmaceuticals common stock. It is coded as “S,” indicating a sale in an open-market or private transaction, and is further described as an open-market sale made to cover RSU-related tax withholding.

Do Wilson Martin’s Rocket Pharmaceuticals (RCKT) holdings include restricted stock units?

Yes. A footnote explains that Wilson Martin’s reported holdings include restricted stock units, or RSUs. These RSUs convert into Rocket Pharmaceuticals common stock on a one-for-one basis when they vest, increasing his direct share ownership at that time.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Wilson Martin

(Last) (First) (Middle)

C/O ROCKET PHARMACEUTICALS, INC.

9 CEDARBROOK DRIVE

(Street)

CRANBURY NJ 08512

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ROCKET PHARMACEUTICALS, INC. [ RCKT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	General Counsel

3. Date of Earliest Transaction (Month/Day/Year)
02/13/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock(1)	02/13/2026		S(2)		12,253	D	$3.312	683,376(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis.

2. The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs.

	/s/ Martin Louis Wilson	02/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.